CytomX Therapeutics, Inc.
650 Gateway Boulevard
South San Francisco
75 articles with CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced the appointment of Amy C. Peterson, M.D., as executive vice president and chief development officer
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
CytomX Therapeutics, Inc. announced the second target selection by its partner AbbVie under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
Bristol-Myers Squibb and South San Francisco-based CytomX Therapeutics have been collaborating since 2014, a deal that was boosted in 2017 when Bristol-Myers Squibb added up to eight additional targets using CytomX’s Probody platform.
CytomX Therapeutics 2019 Research and Development Day Highlights Clinical Data from Lead Programs and the Broad Potential of Probody™ Therapeutic Platform
CX-2009, a First-in-Class Probody Drug Conjugate Targeting CD166, Demonstrates Encouraging Anti-Cancer Activity in Multiple Tumor Types and Safety in Phase 1 Dose Escalation
In March venture capital firm ShangPharma Innovations announced its plans to expand its life sciences incubator in San Francisco by 40 percent, including state-of-the-art laboratory infrastructure upgrades to its facility. That investment is paying off as the incubator is growing.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
This week Pfizer notified the Bay Area-based company of its intent to terminate its five-year-old oncology collaboration.
Bristol-Myers Squibb acquisition of IFM Therapeutics, and Amgen-CytomX licensing deal recognized among more than 4,000 transactions in annual Cortellis Deal of the Year Awards from Clarivate Analytics
CytomX Therapeutics today announced that the company has been added to the NASDAQ Biotechnology Index effective December 18th, 2017.
Medidata Expands Partnership With CytomX Therapeutics to Centralize Management of Regulated and Nonregulated Content
With the addition of Medidata RCM, CytomX will now manage regulated and nonregulated content in a single, unified platform.
CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 P...
11/28/2017The IND acceptance results in a $10 million milestone payment to CytomX.
As of September 30, 2017, CytomX had cash, cash equivalents and short-term investments of $331.3 million.
The company will not conduct a conference call in conjunction with this financial results press release.
Dr. Fuchs is an internationally recognized expert in gastrointestinal cancers, cancer epidemiology and cancer drug development.
CytomX Achieves Development Milestone In Strategic Oncology Collaboration With AbbVie For CD71-Targeting Probody Drug Conjugate